Organogenesis Holdings Inc. (ORGO)
USD 5.28
(6.45%)
USD 5.28
(6.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 309.79 Million USD | -10.43% |
| 2022 | 345.87 Million USD | -2.26% |
| 2021 | 353.86 Million USD | 40.99% |
| 2020 | 250.97 Million USD | 35.64% |
| 2019 | 185.03 Million USD | 48.45% |
| 2018 | 124.64 Million USD | 2814.41% |
| 2017 | -4.59 Million USD | -2100.23% |
| 2016 | -208.69 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 96.62 Million USD | 24.49% |
| 2024 Q1 | 77.61 Million USD | 14.51% |
| 2023 Q1 | 81.03 Million USD | -8.34% |
| 2023 FY | 309.79 Million USD | -10.43% |
| 2023 Q4 | 67.78 Million USD | -18.08% |
| 2023 Q3 | 82.74 Million USD | -9.07% |
| 2023 Q2 | 91 Million USD | 12.3% |
| 2022 Q2 | 94.74 Million USD | 29.73% |
| 2022 Q1 | 73.03 Million USD | -23.89% |
| 2022 FY | 345.87 Million USD | -2.26% |
| 2022 Q4 | 88.4 Million USD | -2.51% |
| 2022 Q3 | 90.68 Million USD | -4.29% |
| 2021 Q2 | 93.25 Million USD | 21.02% |
| 2021 FY | 353.86 Million USD | 40.99% |
| 2021 Q1 | 77.05 Million USD | -5.2% |
| 2021 Q4 | 95.96 Million USD | 9.56% |
| 2021 Q3 | 87.58 Million USD | -6.08% |
| 2020 Q2 | 48.91 Million USD | 13.92% |
| 2020 FY | 250.97 Million USD | 35.64% |
| 2020 Q4 | 81.28 Million USD | 4.44% |
| 2020 Q3 | 77.83 Million USD | 59.11% |
| 2020 Q1 | 42.93 Million USD | -20.86% |
| 2019 Q1 | 40.14 Million USD | -12.9% |
| 2019 FY | 185.03 Million USD | 48.45% |
| 2019 Q4 | 54.25 Million USD | 20.21% |
| 2019 Q3 | 45.13 Million USD | -0.81% |
| 2019 Q2 | 45.5 Million USD | 13.35% |
| 2018 Q3 | -2.24 Million USD | -138.61% |
| 2018 Q4 | 46.08 Million USD | 2149.32% |
| 2018 FY | 124.64 Million USD | 2814.41% |
| 2018 Q1 | -1.15 Million USD | -121.91% |
| 2018 Q2 | -942.52 Thousand USD | 18.67% |
| 2017 Q2 | -221.8 Thousand USD | -1.45% |
| 2017 Q3 | -2.85 Million USD | -1186.31% |
| 2017 FY | -4.59 Million USD | -2100.23% |
| 2017 Q4 | 5.28 Million USD | 285.37% |
| 2017 Q1 | -218.64 Thousand USD | -86.76% |
| 2016 FY | -208.69 Thousand USD | 0.0% |
| 2016 Q2 | -500.00 USD | 96.78% |
| 2016 Q4 | -117.07 Thousand USD | -707.84% |
| 2016 Q3 | -14.49 Thousand USD | -2798.4% |
| 2016 Q1 | -15.55 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -1.47% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -941.241% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 5.022% |
| Cosmos Health Inc. | 4.34 Million USD | -7022.315% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 12953.418% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -323.981% |
| Cronos Group Inc. | 6.99 Million USD | -4331.335% |
| Incannex Healthcare Limited | 12 Thousand USD | -2581483.333% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 102340.924% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -640.239% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 41649.757% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -3614.878% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -3614.878% |
| SCYNEXIS, Inc. | 124.51 Million USD | -148.793% |
| Safety Shot Inc | -74.45 Thousand USD | 416165.649% |
| Theratechnologies Inc. | 62.12 Million USD | -398.624% |
| Alpha Teknova, Inc. | 10.29 Million USD | -2908.838% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -2973.96% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 36.817% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -6428.767% |
| Dynavax Technologies Corporation | 182.11 Million USD | -70.105% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 29.778% |
| Radius Health, Inc. | 307.71 Million USD | -0.676% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -55821.7% |
| Alvotech | -69.42 Million USD | 546.242% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 28.06% |
| SIGA Technologies, Inc. | 122.09 Million USD | -153.735% |
| Shineco, Inc. | 882.16 Thousand USD | -35016.894% |
| Silver Spike Investment Corp. | 8.1 Million USD | -3723.341% |
| Journey Medical Corporation | 52.52 Million USD | -489.84% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -7291.496% |
| Embecta Corp. | 749.9 Million USD | 58.689% |
| Harrow Health, Inc. | 90.55 Million USD | -242.109% |
| Procaps Group, S.A. | 239.56 Million USD | -29.311% |
| Biofrontera Inc. | 16.62 Million USD | -1763.174% |
| DURECT Corporation | 6.83 Million USD | -4435.061% |
| PainReform Ltd. | -15 Thousand USD | 2065366.667% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 40.851% |
| OptiNose, Inc. | 62.35 Million USD | -396.825% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -10043.171% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -825.136% |
| ProPhase Labs, Inc. | 16.23 Million USD | -1807.691% |
| Phibro Animal Health Corporation | 312.48 Million USD | 0.863% |
| Procaps Group S.A. | 239.56 Million USD | -29.311% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -23693.395% |
| Viatris Inc. | 6.43 Billion USD | 95.189% |
| Rockwell Medical, Inc. | 8.7 Million USD | -3459.168% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -467.526% |
| Tilray Brands, Inc. | 223.35 Million USD | -38.701% |
| PetIQ, Inc. | 252.74 Million USD | -22.573% |
| Talphera, Inc. | -4.89 Million USD | 6428.703% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 83.231% |
| Alimera Sciences, Inc. | 61.17 Million USD | -406.441% |
| Assertio Holdings, Inc. | 125.04 Million USD | -147.735% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 4548477.624% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1042.42% |
| Hempacco Co., Inc. | -1.21 Million USD | 25579.651% |
| Alvotech | -69.42 Million USD | 546.242% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 56.34% |
| Kamada Ltd. | 52.59 Million USD | -489.036% |
| Currenc Group, Inc. | 17.35 Million USD | -1684.885% |
| Indivior PLC | 907 Million USD | 65.845% |
| Evoke Pharma, Inc. | 4.97 Million USD | -6122.243% |
| Flora Growth Corp. | 17.73 Million USD | -1646.476% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 12953.418% |
| Evolus, Inc. | 140.52 Million USD | -120.45% |
| HUTCHMED (China) Limited | 453.55 Million USD | 31.697% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 9.936% |
| Akanda Corp. | 111.44 Thousand USD | -277865.706% |